Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Imatinib and Nilotinib Intracytoplasmic Determination Levels.

Stephane Bouchet, Stephanie Dulucq, Karine Titier, Nicholas Moore, Mathieu Molimard, Francois-Xavier Mahon

Blood (2009) 114 (22): 2750.

https://doi.org/10.1182/blood.V114.22.2750.2750

Published: 2009

Journal Articles

Management of Chronic Myelogenous Leukemia Using Therapeutic Drug Monitoring of Imatinib: The French Experience of a Centralized Laboratory

Mathieu Molimard, Stephane Bouchet, Gabriel Etienne, Laurence Legros, Delphine Rea, Francoise Huguet, Karine Titier, Nicholas Moore, Josy Reiffers, Coralie Belanger, Francois-Xavier Mahon

Blood (2008) 112 (11): 3222.

https://doi.org/10.1182/blood.V112.11.3222.3222

Published: 2008

Journal Articles

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

Stephane Picard, Karine Titier, Gabriel Etienne, Emmanuelle Teilhet, Dominique Ducint, Marie-Agnes Bernard, Regis Lassalle, Gerald Marit, Josy Reiffers, Bernard Begaud, Nicholas Moore, Mathieu Molimard, Francois-Xavier Mahon

Blood (2006) 109 (8): 3496–3499.

https://doi.org/10.1182/blood-2006-07-036012

Published: 2006

Journal Articles

Trough Plasma Imatinib Concentrations Are Associated with Both Cytogenetic and Molecular Responses to Standard-Dose Imatinib in Chronic Myeloid Leukemia.

Stephane Picard, MD, Karine Titier, Pharm D, Gabriel Etienne, MD, Regis Lassalle, MSc, Gerald Marit, MD, Josy Reiffers, MD, Bernard Begaud, MD, Nicholas Moore, MD,PhD, Mathieu Molimard, MD,PhD, Francois-Xavier Mahon, MD,PhD

Blood (2006) 108 (11): 2141.

https://doi.org/10.1182/blood.V108.11.2141.2141

Published: 2006

Journal Articles

Quantification of Imatinib in Human Plasma by High Performance Liquid Chromatography-Tandem Mass Spectrometry: Applications to Therapeutic Drug Monitoring of Patients with Chronic Myelogenous Leukemia.

Francois-Xavier Mahon, MD, PhD, Stéphane Picard, MD, Karine Titier, MD, Franck Nicolini, MD, PhD, Dominique Ducint, MD, Nicolas Moore, MD, PhD, Gerald Marit, MD, Patrice Berthaud, MD, Mathieu Molimard, MD, PhD

Blood (2005) 106 (11): 1995.

https://doi.org/10.1182/blood.V106.11.1995.1995

Published: 2005

NARROW

Imatinib and Nilotinib Intracytoplasmic Determination Levels.

Management of Chronic Myelogenous Leukemia Using Therapeutic Drug Monitoring of Imatinib: The French Experience of a Centralized Laboratory

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

Trough Plasma Imatinib Concentrations Are Associated with Both Cytogenetic and Molecular Responses to Standard-Dose Imatinib in Chronic Myeloid Leukemia.

Quantification of Imatinib in Human Plasma by High Performance Liquid Chromatography-Tandem Mass Spectrometry: Applications to Therapeutic Drug Monitoring of Patients with Chronic Myelogenous Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Imatinib and Nilotinib Intracytoplasmic Determination Levels.

Management of Chronic Myelogenous Leukemia Using Therapeutic Drug Monitoring of Imatinib: The French Experience of a Centralized Laboratory

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

Trough Plasma Imatinib Concentrations Are Associated with Both Cytogenetic and Molecular Responses to Standard-Dose Imatinib in Chronic Myeloid Leukemia.

Quantification of Imatinib in Human Plasma by High Performance Liquid Chromatography-Tandem Mass Spectrometry: Applications to Therapeutic Drug Monitoring of Patients with Chronic Myelogenous Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only